Biomet agrees to $56 million hip replacement settlement, Notes Hissey Kientz, LLP

News provided by

Hissey Kientz LLP

Feb 05, 2014, 10:30 ET

Austin, Texas (PRWEB) February 05, 2014 -- Biomet Inc has announced that it will pay at least $56 million to settle hundreds of Biomet M2a Magnum hip replacement lawsuits. The Biomet lawsuits were consolidated into a multidistrict litigation and jointly heard at the federal court of Indiana. The settlement agreement was approved by U.S. District Judge Robert L. Miller Jr. on Monday.*

The Biomet multidistrict ligation began in October 2012 and includes over 700 lawsuits. The Biomet lawsuits claim that that the metal-on-metal design of the Biomet M2a Magnum hip replacement can lead to metallosis, a form of metal poisoning, or early device failure. (In re: Biomet M2a Magnum Hip Implant Products Liability Litigation – MDL No. 2391)

In January 2013, the U.S. Food and Drug Administration issued a warning stating that metal-on-metal hip replacements, such as the BioMet M2a Magnum, can increase the risk of severe complications including hip implant loosening, bone and tissue damage, metal poisoning and premature device failure.**

The BioMet M2a Magnum hip replacements were approved under the Food and Drug Administration’s 510(k) program, a process which allows devices to come to market without first undergoing human clinical trials. In January 2013, the FDA issued a proposed order that would make all metal-on-metal hip replacements ineligible for 510(k) approvals.***

Patients who have experienced metal poisoning, tissue damage or premature device failure after receiving a BioMet M2a Magnum hip replacement may wish to speak with a lawyer to find out if they are eligible to file a lawsuit. For more information about whether you may have a case, contact the attorneys at Hissey Kientz, LLP by calling toll-free at 1-866-275-4454, or by email at info(at)hkllp(dot)com.

*http://www.reuters.com/article/2014/02/04/us-biomet-settlement-idUSBREA1305Y20140204

**http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/ucm241604.htm

*** https://www.federalregister.gov/articles/2013/01/18/2013-01006/effective-date-of-requirement-for-premarket-approval-for-two-class-iii-preamendments-devices

About Hissey Kientz, LLP
Hissey Kientz, LLP (http://www.hkllp.com) represents individuals experiencing complications from BioMet hip replacements, as well as victims of mesothelioma and other asbestos-related diseases, birth defects linked to the antidepressant drugs Zoloft, Lexapro, Celexa and Effexor, problems with transvaginal mesh, Stryker and DePuy hip replacements, GranuFlo acid concentrates, Mirena IUDs and other defective drugs and medical devices.

Allison Sass, Hissey Kientz LLP, http://www.hkllp.com, +1 (866) 275-4454, [email protected]